Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 26:11:558.
doi: 10.3389/fpsyt.2020.00558. eCollection 2020.

Expert Opinions and Consensus Recommendations for the Evaluation and Management of Insomnia in Clinical Practice: Joint Statements of Five Italian Scientific Societies

Affiliations

Expert Opinions and Consensus Recommendations for the Evaluation and Management of Insomnia in Clinical Practice: Joint Statements of Five Italian Scientific Societies

Laura Palagini et al. Front Psychiatry. .

Abstract

Background: Insomnia is the most commonly reported sleep problem in industrialized countries worldwide being present in about 36.8% of the general population. In Italy, such a percentage seems to be even higher. Although insomnia can be an independent disorder, it is most frequently observed as a comorbid condition and may precipitate, exacerbate, or prolong a broad range of comorbid conditions including physical and mental illnesses. Evaluating and targeting insomnia in the Italian clinical practice should be a priority.

Methods: The present expert options and recommendations development process was based on the RAND/UCLA Appropriateness Method for conceptualizing, designing, and carrying out the appropriateness of procedures for the diagnosis and treatment. Only available options in Italy were taken into considerations.

Results: We evaluated 12 international guidelines and 12 most recent systematic reviews for insomnia evaluation and treatment produced in the last 10 years.

Conclusions: Our findings suggested that symptoms of insomnia must always be assessed in the Italian clinical practice by evaluating nocturnal and daytime symptoms, comorbid conditions and lifestyle. In a patient with chronic insomnia with and without comorbidity, insomnia treatment should be always initiated. CBT-Insomnia therapy should be the first option accordingly to availability. The choice of the drug should be based on different factors such as type of insomnia, age, comorbidities, and potential side effects. Melatonin 2 mg prolonged release should be the first choice in subjects >55 years. If the choice would be a Z-drug or a short-acting benzodiazepine (in subjects <65 years old) or a sedating antidepressant, the use should be in the short term (≤4 weeks) and then proceeds to tapering under clinical monitoring.

Keywords: clinical practice; consensus recommendations; evaluation; expert opinions; insomnia; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expert opinions and consensus recommendations process. The development process was based on the RAND/UCLA Appropriateness Method for conceptualizing, designing, and carrying out the appropriateness of procedures for the diagnosis and treatment. The method consists of a modified Delphi approach in which a panel of Italian experts assessed the appropriateness of particular clinical decisions in an iterative way.
Figure 2
Figure 2
Expert opinions and consensus recommendations on the Evaluation and treatment of insomnia in the clinical practice. Z-drugs: Zolpidem, Zaleplon, and Zopiclone; BDZ: benzodiazepines.

References

    1. Ohayon MM, Smirne S. Prevalence and consequences of insomnia disorders in the general population of Italy. Sleep Med (2002) 3:115–20. 10.1016/S1389-9457(01)00158-7 - DOI - PubMed
    1. Terzano MG, Parrino L, Bonanni E, Cirignotta F, Ferrillo F, Gigli GL, et al. Insomnia in general practice : a consensus report produced by sleep specialists and primary-care physicians in Italy. Clin Drug Investig (2005) 25:745–64. 10.2165/00044011-200525120-00002 - DOI - PubMed
    1. Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol (2010) 24:1577–601. 10.1177/0269881110379307 - DOI - PubMed
    1. Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res (2017) 26:675–700. 10.1111/jsr.12594 - DOI - PubMed
    1. Wilson S, Anderson K, Baldwin D, Dijk DJ, Espie CA, Gringras P, et al. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update. J Psychopharmacol (2019) 33:923–47. 10.1177/0269881119855343 - DOI - PubMed

Publication types

LinkOut - more resources